Analysts expect Kura Oncology, Inc. (NASDAQ:KURA) to report $-0.36 EPS on May, 21.They anticipate $0.03 EPS change or 7.69% from last quarter’s $-0.39 EPS. After having $-0.37 EPS previously, Kura Oncology, Inc.’s analysts see -2.70% EPS growth. The stock decreased 1.15% or $0.2 during the last trading session, reaching $17.15. About 58,920 shares traded. Kura Oncology, Inc. (NASDAQ:KURA) has risen 116.28% since April 16, 2017 and is uptrending. It has outperformed by 104.73% the S&P500.
Icu Medical Inc (ICUI) investors sentiment increased to 1.19 in 2017 Q4. It’s up 0.33, from 0.86 in 2017Q3. The ratio has increased, as 102 investment managers increased or opened new stock positions, while 86 sold and reduced their holdings in Icu Medical Inc. The investment managers in our database now have: 15.21 million shares, down from 15.58 million shares in 2017Q3. Also, the number of investment managers holding Icu Medical Inc in top ten stock positions decreased from 3 to 2 for a decrease of 1. Sold All: 11 Reduced: 75 Increased: 66 New Position: 36.
Since January 1, 0001, it had 0 insider buys, and 6 insider sales for $40.42 million activity.
Pura Vida Investments Llc holds 5.6% of its portfolio in ICU Medical, Inc. for 35,000 shares. Lyon Street Capital Llc owns 28,280 shares or 2.04% of their US portfolio. Moreover, Sandhill Capital Partners Llc has 1.98% invested in the company for 51,657 shares. The New York-based Atika Capital Management Llc has invested 1.59% in the stock. Redmile Group Llc, a California-based fund reported 139,972 shares.
Analysts await ICU Medical, Inc. (NASDAQ:ICUI) to report earnings on May, 9. They expect $1.62 earnings per share, up 9.46% or $0.14 from last year’s $1.48 per share. ICUI’s profit will be $32.86 million for 39.65 P/E if the $1.62 EPS becomes a reality. After $2.70 actual earnings per share reported by ICU Medical, Inc. for the previous quarter, Wall Street now forecasts -40.00% negative EPS growth.
ICU Medical, Inc. develops, manufactures, and sells medical devices used in infusion therapy, critical care, and oncology applications worldwide. The company has market cap of $5.21 billion. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patientÂ’s vein for use in hospitals and ambulatory clinics. It has a 78.09 P/E ratio. The companyÂ’s infusion therapy products include needlefree connector products, such as MicroClave and MicroClave Clear, Neutron, NanoClave, Clave, and SwabCap; custom infusion sets; and Tego needlefree hemodialysis connectors.
The stock increased 0.42% or $1.07 during the last trading session, reaching $256.92. About 53,801 shares traded. ICU Medical, Inc. (ICUI) has risen 61.26% since April 16, 2017 and is uptrending. It has outperformed by 49.71% the S&P500.